诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVO 诺和诺德

已收盘 04-23 16:00:00 EDT

61.30

+1.39

+2.32%

盘后62.09

+0.79+1.29%

19:59 EDT

最高62.43	最低60.89	成交量912.87万
今开61.77	昨收59.91	日振幅2.57%
总市值2,721亿	流通市值1,952亿	总股本44.39亿
成交额5.62亿	换手率0.29%	流通股本31.84亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVO","market":"US","secType":"STK","nameCN":"诺和诺德","latestPrice":61.3,"timestamp":1745438400000,"preClose":59.91,"halted":0,"volume":9128730,"hourTrading":{"tag":"盘后","latestPrice":62.0899,"preClose":61.3,"latestTime":"19:59 EDT","volume":232255,"amount":14294489.8958,"timestamp":1745452776934},"delay":0,"floatShares":3183551536,"shares":4439052849,"eps":3.141546,"marketStatus":"已收盘","change":1.39,"latestTime":"04-23 16:00:00 EDT","open":61.77,"high":62.43,"low":60.89,"amount":562374918.69858,"amplitude":0.025705,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.141546,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1745481600000},"marketStatusCode":5,"adr":1,"adrRate":1,"listingDate":363499200000,"exchange":"NYSE","adjPreClose":59.91,"dividendRate":0.02737,"preHourTrading":{"tag":"盘前","latestPrice":61.76,"preClose":59.91,"latestTime":"09:29 EDT","volume":419464,"amount":25742108.447592,"timestamp":1745414999999},"postHourTrading":{"tag":"盘后","latestPrice":62.0899,"preClose":61.3,"latestTime":"19:59 EDT","volume":232255,"amount":14294489.8958,"timestamp":1745452776934},"volumeRatio":0.655931,"impliedVol":0.574,"impliedVolPercentile":0.888},"requestUrl":"/m/hq/s/NVO","defaultTab":"news","newsList":[{"id":"2529631611","title":"诺和诺德盘中异动 股价大涨3.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529631611","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529631611?lang=zh_cn&edition=full","pubTime":"2025-04-23 21:33","pubTimestamp":1745415201,"startTime":"0","endTime":"0","summary":"北京时间2025年04月23日21时33分，诺和诺德股票出现异动，股价快速拉升3.66%。诺和诺德股票所在的制药行业中，整体涨幅为0.83%。诺和诺德还有一个生物制药部门，专门从事血友病和其他疾病的蛋白质疗法。消息层面，截至21时33分，《减肥药双雄死磕口服新战场减肥药双雄死磕口服新战场》资讯为影响诺和诺德的重要信息。结果公布后，诺和诺德计划在2023年提交上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423213321a463fa08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423213321a463fa08&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","LU0154236417.USD","NVO","BK4532","LU1093756168.USD","IE00BZ1G4Q59.USD","BK4599","IE00BKVL7J92.USD","BK4007","BK4585","BK4588"],"gpt_icon":1},{"id":"2529906524","title":"迎战礼来，诺和诺德抢先递交口服 GLP-1减重上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2529906524","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529906524?lang=zh_cn&edition=full","pubTime":"2025-04-23 15:32","pubTimestamp":1745393520,"startTime":"0","endTime":"0","summary":"诺和诺德向FDA递交口服司美格鲁肽减重适应症的上市申请，该药物在III期临床试验中显示显著减重效果，此举意在抢占口服减重市场先发优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504231608319741d2b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504231608319741d2b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2552382132.HKD","LU2112291526.USD","LU1064131342.USD","LU0097036916.USD","SG9999017495.SGD","BK4581","SGXZ51526630.SGD","LU0109391861.USD","LU0882574055.USD","LU2237438978.USD","LU2237443978.SGD","LU0708995401.HKD","LU1366192091.USD","SGXZ81514606.USD","LU0466842654.USD","IE00BK4W5M84.HKD","LU0672654240.SGD","LU1057294990.SGD","LU1551013425.SGD","LU1917777945.USD","LU1868836591.USD","LU0385154629.USD","LU1988902786.USD","LU1267930730.SGD","LU2471134952.CNY","BK4590","IE00B2B36J28.USD","LU0203201768.USD","LU0256863811.USD","GB00BDT5M118.USD","IE00BJT1NW94.SGD","LU2468319806.SGD","LU1093756168.USD","NVO","SG9999013999.USD","SG9999014914.USD","LU1983299246.USD","LU2237443382.USD","LU1035775433.USD","LU0417517546.SGD","LU1868837136.USD","LLY","IE00BZ1G4Q59.USD","GLP","LU1232071149.USD","IE00BFTCPJ56.SGD","LU1069344957.HKD","LU1623119135.USD","LU0238689110.USD","BK4534"],"gpt_icon":0},{"id":"2529251860","title":"诺和诺德4月22日成交额为6.98亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529251860","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529251860?lang=zh_cn&edition=full","pubTime":"2025-04-23 10:11","pubTimestamp":1745374270,"startTime":"0","endTime":"0","summary":"美东时间2025年4月22日，诺和诺德成交额为6.98亿美元，成交额较昨日减少10.34%，当日成交量为1169.79万股。诺和诺德于2025年4月22日涨2.71%，报59.91美元，该股过去5个交易日跌9.31%，年初至今跌29.52%，过去60日跌31.08%。诺和诺德还有一个生物制药部门，专门从事血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423101111a4633c6e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423101111a4633c6e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","IE00BKVL7J92.USD","BK4585","BK4532","NVO","IE00BZ1G4Q59.USD","BK4599","LU0154236417.USD","BK4588","LU1093756325.SGD","LU1093756168.USD"],"gpt_icon":1},{"id":"2529213530","title":"欧股“十一罗汉”收盘播报｜诺和诺德收跌超7.4%，欧莱雅则涨6.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529213530","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529213530?lang=zh_cn&edition=full","pubTime":"2025-04-23 01:35","pubTimestamp":1745343302,"startTime":"0","endTime":"0","summary":"周二，阿斯麦控股荷兰阿姆斯特丹股价收跌0.55%，报561.10欧元。诺和诺德哥本哈根股价收跌7.43%，报390.00，逼近2022年9月23日底部365.30，2024年6月26日还曾涨至1033.20创盘中历史最高。德国思爱普Sap收跌3.32%，雀巢跌1.5%，罗氏跌0.31%，诺华、阿斯利康、LVMH集团、赛诺菲则至多收涨0.5%，葛兰素史克张1.93%，欧莱雅涨6.30%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504230136379740f1a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504230136379740f1a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","IE00BKVL7J92.USD","BK4585","BK4183","LU0154236417.USD","BK4532","IE00BZ1G4Q59.USD","NVO","BK4599","LU1093756325.SGD","LU1093756168.USD","BK4588","LRLCY"],"gpt_icon":0},{"id":"2529721535","title":"明晟公司MSCI北欧国家指数微幅下跌，报326.01点，北欧医疗保健板块领跌。诺和诺德跌7.4%，在一众成分股里表现最差。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529721535","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529721535?lang=zh_cn&edition=full","pubTime":"2025-04-22 23:40","pubTimestamp":1745336434,"startTime":"0","endTime":"0","summary":"明晟公司MSCI北欧国家指数微幅下跌，报326.01点，北欧医疗保健板块领跌。诺和诺德跌7.4%，在一众成分股里表现最差。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/22234049770680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1267930730.SGD","LU0175139822.USD","LU2095319765.USD","BK4599","LU0708995401.HKD","NVO","LU1093756325.SGD","MSCI","LU0672654240.SGD","LU0289739343.SGD","LU0109391861.USD","BK4007","LU2210150020.SGD","BK4585","LU1804176565.USD","LU0154236417.USD","BK4588","BK4532","LU0511384066.AUD","LU0289961442.SGD","LU2265009873.SGD","LU0320765059.SGD","LU2210149790.SGD","LU0289960550.SGD","BK4112","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU1093756168.USD"],"gpt_icon":0},{"id":"2529580968","title":"诺和诺德盘中异动 股价大涨3.00%报60.08美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529580968","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529580968?lang=zh_cn&edition=full","pubTime":"2025-04-22 22:46","pubTimestamp":1745333167,"startTime":"0","endTime":"0","summary":"北京时间2025年04月22日22时46分，诺和诺德股票出现异动，股价大幅拉升3.00%。截至发稿，该股报60.08美元/股，成交量487.427万股，换手率0.11%，振幅1.95%。诺和诺德股票所在的制药行业中，整体涨幅为0.34%。诺和诺德公司简介：诺和诺德拥有全球约三分之一的品牌糖尿病治疗市场，是全球领先的糖尿病护理产品供应商。诺和诺德还有一个生物制药部门，专门从事血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422224607a4629ae8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422224607a4629ae8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVO","IE00BKVL7J92.USD","BK4532","LU1093756168.USD","LU1093756325.SGD","BK4007","LU0154236417.USD","BK4585","BK4599","BK4588","IE00BZ1G4Q59.USD"],"gpt_icon":1},{"id":"2529589604","title":"司美格鲁肽大消息！诺和诺德首次官宣","url":"https://stock-news.laohu8.com/highlight/detail?id=2529589604","media":"健识局","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529589604?lang=zh_cn&edition=full","pubTime":"2025-04-22 19:58","pubTimestamp":1745323117,"startTime":"0","endTime":"0","summary":"4月21日，诺和诺德与京东健康达成战略合作，将进一步加深在糖尿病和体重管理领域的共建。同时，诺和诺德还首次将“诺和泰”、“诺和忻”等多款不同适应症、不同剂型的司美格鲁肽正式搬到电商平台销售，开创中国GLP-1药物销售格局的先河。司美格鲁肽上市已久，但却是第一次官方正式“上网”，这或许与近期一系列话题有关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422200904a4627310&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422200904a4627310&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1591","BK1247","NVO","BK1589","86618","06618","BK1583","BK1515","LU0051755006.USD","BK1615","LU0456827905.SGD","BK1142","BK1571"],"gpt_icon":1},{"id":"2529336328","title":"礼来Zepbound效果显著，诺和诺德在哥本哈根暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2529336328","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529336328?lang=zh_cn&edition=full","pubTime":"2025-04-22 16:41","pubTimestamp":1745311260,"startTime":"0","endTime":"0","summary":"诺和诺德股价周四在哥本哈根暴跌，原因在于其竞争对手礼来推出的一种新药Zepbound在减肥和控制血糖方面表现出与诺和诺德的重磅注射药物Ozempic相当的效果。自周四礼来公布这一利好消息后，诺和诺德股价在哥本哈根早盘交易中下跌了9.8%，跌至380克朗。其Zepbound不仅疗效媲美注射剂型，更展现出更优的耐受性和用药依从性，这对长期依赖注射给药维持疗效的诺和诺德构成双重打击。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042216425394ddda39&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042216425394ddda39&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0203201768.USD","LU2552382132.HKD","SG9999017495.SGD","LU0061475181.USD","LU1064131342.USD","LU2357305700.SGD","LU2602419157.SGD","SGXZ81514606.USD","LU0882574055.USD","LU2491050071.SGD","LU1868836757.USD","LU2063271972.USD","SG9999014906.USD","LU0006306889.USD","LU0689472784.USD","LU2461242641.AUD","LU1291159041.SGD","LU0823416689.USD","LU1814569148.SGD","LU1983299246.USD","LU0106261372.USD","LU0058720904.USD","IE00BJT1NW94.SGD","BK4533","BK4532","LLY","SG9999001176.USD","LU1868837300.USD","LU0079474960.USD","LU0114720955.EUR","LU0198837287.USD","LU0256863811.USD","LU1366192091.USD","NVO","LU0820561909.HKD","LU2264538146.SGD","SGXZ51526630.SGD","LU0456855351.SGD","IE00BFTCPJ56.SGD","BK4581","LU1868836591.USD","LU2750360641.GBP","SG9999013999.USD","LU0094547139.USD","LU2552382215.SGD","LU0385154629.USD","IE0009355771.USD","LU2491049909.HKD","LU0354030511.USD","SG9999014914.USD"],"gpt_icon":1},{"id":"2529399800","title":"“减肥神药”迈向口服时代！诺和诺德申请美国批准口服版Wegovy","url":"https://stock-news.laohu8.com/highlight/detail?id=2529399800","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529399800?lang=zh_cn&edition=full","pubTime":"2025-04-22 15:40","pubTimestamp":1745307641,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺和诺德今年早些时候向美国FDA提交了一份申请，寻求批准其重磅GLP-1减肥药Wegovy 的口服版本。诺和诺德在2023年5月公布了新型口服司美格鲁肽的3期积极数据。竞争对手礼来早些时候公布，其口服减肥药Orforglipron在三期临床试验中表现出色。服用Orforglipron的患者平均减轻16磅，相当于体重的7.9%。截至周一美股收盘，诺和诺德涨0.43%，礼来跌2.6%。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1282075.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"“减肥神药”迈向口服时代！诺和诺德申请美国批准口服版Wegovy","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NVO","BK4532","LU1093756325.SGD","BK4585","BK4588","IE00BZ1G4Q59.USD","BK4599","IE00BKVL7J92.USD","BK4007","LU0154236417.USD","LU1093756168.USD"],"gpt_icon":0},{"id":"2529958348","title":"诺和诺德股价下跌9.8%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529958348","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529958348?lang=zh_cn&edition=full","pubTime":"2025-04-22 15:07","pubTimestamp":1745305638,"startTime":"0","endTime":"0","summary":"诺和诺德股价下跌9.8%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/22150749745536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4007","IE00BKVL7J92.USD","LU1093756168.USD","LU1093756325.SGD","BK4588","IE00BZ1G4Q59.USD","NVO","LU0154236417.USD","BK4585","BK4532","BK4599"],"gpt_icon":0},{"id":"2529539359","title":"诺和诺德与京东健康开启战略合作，将共同打造肥胖症科普专区","url":"https://stock-news.laohu8.com/highlight/detail?id=2529539359","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529539359?lang=zh_cn&edition=full","pubTime":"2025-04-22 10:05","pubTimestamp":1745287505,"startTime":"0","endTime":"0","summary":"新京报讯（记者王卡拉）4月21日，京东健康与诺和诺德在北京签署战略合作协议，将携手打造肥胖症公众科普专区，助力糖尿病一站式诊疗，全面赋能慢病管理数字化转型升级。为了应对严重慢性疾病的挑战，我国将“糖尿病防治行动”列为《健康中国行动（2019-2030年）》15个专项行动之一，并持续推进《“体重管理年”活动实施方案》。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504223384063334.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504223384063334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK4585","BK4007","BK1571","LU0456827905.SGD","BK1247","06618","LU1093756168.USD","LU0051755006.USD","BK1583","BK1589","LU0154236417.USD","IE00BKVL7J92.USD","BK1142","NVO","86618","BK4588","IE00BZ1G4Q59.USD","BK4599","LU1093756325.SGD","BK1591","BK4532","BK1615"],"gpt_icon":1},{"id":"2529809010","title":"金十数据整理：每日美股市场要闻速递（4月21日，周一）","url":"https://stock-news.laohu8.com/highlight/detail?id=2529809010","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529809010?lang=zh_cn&edition=full","pubTime":"2025-04-21 21:08","pubTimestamp":1745240926,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["GELYY","NVDX","NVDU","80175","US30Y.BOND","NVDD","NVO","NVD2.UK","03439","OEF","US6M.BOND","MSTX","SDS","NVDY","09008","BTC.USD.HKCC","US7Y.BOND","MSTU","IBIT","SNVD.UK","09439","SPY","HK0000934320.USD","ESmain","TSYW.SI","03008","00175","03042","NVDS",".SPX","2NVD.UK","MSTR","EVS.SI","3NVD.UK","NVDA","US10Y.BOND","US3Y.BOND","NVIW.SI","IVV","SPXU","US5Y.BOND","NVDL","US2Y.BOND","TSLL","AZN","SH","TSLA","US12M.BOND","09042","NVD"],"gpt_icon":0},{"id":"2529765368","title":"响应“国家喊你减肥”号召，诺和诺德与京东健康开启战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2529765368","media":"广州日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529765368?lang=zh_cn&edition=full","pubTime":"2025-04-21 17:56","pubTimestamp":1745229391,"startTime":"0","endTime":"0","summary":"生物制药公司诺和诺德与京东健康4月21日正式签署战略合作协议，双方在糖尿病和体重管理领域的合作由此进入新阶段。依托诺和诺德百年深耕慢病领域的专业经验和创新治疗方案，并借助京东健康的全场景医疗服务能力，双方将携手打造肥胖症公众科普专区，助力糖尿病一站式诊疗，全面赋能慢病管理数字化转型升级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504213383080939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NVO","BK1583","BK1615","06618","BK4588","BK4532","BK1142","BK4599","BK1515","86618","IE00BZ1G4Q59.USD","LU0456827905.SGD","LU0154236417.USD","BK4585","BK1589","BK1247","IE00BKVL7J92.USD","BK4007","BK1571","LU0051755006.USD","LU1093756325.SGD","BK1591","LU1093756168.USD"],"gpt_icon":1},{"id":"2529286718","title":"减重版司美格鲁肽中国说明书更新，纳入心血管获益结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2529286718","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529286718?lang=zh_cn&edition=full","pubTime":"2025-04-21 15:52","pubTimestamp":1745221930,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4183","NVO","IE00BKVL7J92.USD","BK4157","BK4599","MACE","IE00BZ1G4Q59.USD","LU1093756325.SGD","LU0154236417.USD","BK4585","BK4588","BK4532","LU1093756168.USD","BK4007"],"gpt_icon":0},{"id":"2529177858","title":"GLP-1竞争新动向：礼来后来居上？","url":"https://stock-news.laohu8.com/highlight/detail?id=2529177858","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529177858?lang=zh_cn&edition=full","pubTime":"2025-04-21 11:05","pubTimestamp":1745204734,"startTime":"0","endTime":"0","summary":"尽管GLP-1火遍全球，但实际上，现在还没有任何一款GLP-1口服版药物获批了减重适应症。GLP-1尽管看来已经接近完美，但依然有很大的不足。口服药就完全规避了以上所有劣势，从诺和诺德、礼来的开发劲头可以看出，今后GLP-1药物的竞争会逐渐从注射剂转到口服制剂上。口服减肥GLP-1可能会成为礼来反超的一张王牌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250421110753a4606b12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250421110753a4606b12&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2491049909.HKD","LU2112291526.USD","LU0256863902.USD","SGXZ51526630.SGD","LU2471134952.CNY","LU1868836914.USD","LU2324357040.USD","LU2552382132.HKD","LU0114720955.EUR","SG9999014906.USD","LU2063271972.USD","LU0471298777.SGD","LU1868837136.USD","LU1366192091.USD","SG9999001176.SGD","LU0094547139.USD","LU2237443465.HKD","LU1974910355.USD","LU1127390331.HKD","LU1868837300.USD","LU1983299246.USD","GLP","SG9999014914.USD","SG9999015945.SGD","BK4007","LU0882574055.USD","LU0672654240.SGD","LU2237438978.USD","LU2471134523.USD","LU0943347566.SGD","IE00BJJMRZ35.SGD","LU1291159041.SGD","SG9999001176.USD","LU2471134796.USD","LU0006306889.USD","IE00B1BXHZ80.USD","LLY","LU1551013342.USD","LU1548497426.USD","LU2361044949.HKD","IE00BJT1NW94.SGD","LU1551013425.SGD","LU0096364046.USD","LU1917777945.USD","LU1868836591.USD","LU0122379950.USD","LU2237443895.HKD","LU2461242641.AUD","NVO","LU1069344957.HKD","LU1988902786.USD"],"gpt_icon":1},{"id":"2528107268","title":"诺和诺德、礼来“二王争霸”，国产GLP-1抢夺新适应症，恒瑞医药们不想只做减肥神药","url":"https://stock-news.laohu8.com/highlight/detail?id=2528107268","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528107268?lang=zh_cn&edition=full","pubTime":"2025-04-19 17:46","pubTimestamp":1745055988,"startTime":"0","endTime":"0","summary":"GLP-1（胰高血糖素样肽-1）类药物的适应症不只停留在糖尿病与减重领域，赛道中的玩家们正在加速向其他代谢性疾病及神经系统等更广阔的领域扩围。4月14日，药物临床试验登记与信息公示平台官网显示，信达生物（01801.HK）登记了一项评估玛仕度肽（IBI362）在患有中重度阻塞性睡眠呼吸暂停且肥胖的受试者中有效性和安全性的Ⅲ期临床试验（GLORY-OSA）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504193381946449.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2361045086.USD","LU1868837300.USD","LU1917777945.USD","LU0385154629.USD","LLY","LU2468319806.SGD","IE00BJT1NW94.SGD","LU0256863811.USD","LU0096364046.USD","LU0198837287.USD","LU2237438978.USD","LU0708995401.HKD","LU0689472784.USD","LU2264538146.SGD","LU1548497426.USD","NVO","SGXZ99366536.SGD","BK4590","SGXZ57979304.SGD","IE0009355771.USD","BK4599","SG9999014914.USD","LU1093756168.USD","LU0943347566.SGD","BK4585","LU1551013425.SGD","IE00BK4W5M84.HKD","SG9999013999.USD","LU0471298777.SGD","LU1868837136.USD","LU0238689110.USD","LU1057294990.SGD","LU2360106947.USD","LU2471134523.USD","LU1023059063.AUD","LU0471298694.HKD","BK4533","GLP","LU1989771016.USD","BK4007","LU1712237335.SGD","LU2361044865.SGD","SG9999015986.USD","LU0203202063.USD","LU0079474960.USD","LU0466842654.USD","LU1069344957.HKD","LU2552382215.SGD","LU1988902786.USD","LU0114720955.EUR"],"gpt_icon":1},{"id":"2528882380","title":"诺和诺德4月17日成交额为18.73亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528882380","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528882380?lang=zh_cn&edition=full","pubTime":"2025-04-18 10:14","pubTimestamp":1744942451,"startTime":"0","endTime":"0","summary":"美东时间2025年4月17日，诺和诺德成交额为18.73亿美元，成交额较昨日增加368.67%，当日成交量为3222.06万股。诺和诺德于2025年4月17日跌7.63%，报58.08美元，该股过去5个交易日跌5.11%，年初至今跌31.67%，过去60日跌27.05%。诺和诺德还有一个生物制药部门，专门从事血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250418101413a6beb4d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250418101413a6beb4d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU0154236417.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4007","NVO","BK4585","BK4599","IE00BKVL7J92.USD","LU1093756168.USD","BK4532"],"gpt_icon":1},{"id":"2528582745","title":"诺和诺德盘初跌8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2528582745","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528582745?lang=zh_cn&edition=full","pubTime":"2025-04-17 21:47","pubTimestamp":1744897672,"startTime":"0","endTime":"0","summary":"诺和诺德盘初跌8%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504173380246517.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504173380246517.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0154236417.USD","NVO","BK4532","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","BK4585","LU1093756325.SGD","BK4007","BK4599","BK4588","LU1093756168.USD"],"gpt_icon":0},{"id":"2528743174","title":"礼来(LLY)涨超16% 诺和诺德(NVO)跌逾8% Orforglipron研究取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2528743174","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528743174?lang=zh_cn&edition=full","pubTime":"2025-04-17 21:45","pubTimestamp":1744897552,"startTime":"0","endTime":"0","summary":"与此同时，诺和诺德股价走低，跌8.45%，报57.56美元。消息面上，公司宣布III期ACHIEVE-1研究取得积极结果，该研究评估了orforglipron与安慰剂相比在饮食和运动单独控制不佳的2型糖尿病成人中的安全性和疗效。Orforglipron是首个成功完成III期研究的口服小分子胰高血糖素样肽-1受体激动剂，服用时无需食物和水限制。Orforglipron在后期试验中，最高剂量下可使 2 型糖尿病患者体重减轻16.0 磅，并降低血糖。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/M2RkMDMzZDc5MTczNjIzNzY2ODA2Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/M2RkMDMzZDc5MTczNjIzNzY2ODA2Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"287644","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443978.SGD","LU0354030438.USD","LU0689472784.USD","LU0238689110.USD","LU2552382215.SGD","BK4532","LU2552382132.HKD","SGXZ51526630.SGD","SG9999014914.USD","LU0823416689.USD","LU1057294990.SGD","SG9999014880.SGD","LU2471134523.USD","LU2360106947.USD","IE0009355771.USD","LU0672654240.SGD","SG9999015952.SGD","LU2491049909.HKD","SG9999018857.SGD","BK4516","IE00B1BXHZ80.USD","LU0256863902.USD","SGXZ57979304.SGD","IE0004445239.USD","LU0882574139.USD","LU0385154629.USD","SGXZ31699556.SGD","LU0058720904.USD","NVO","LU0097036916.USD","LU1093756168.USD","LU1868837300.USD","LU1623119135.USD","LLY","LU1280957306.USD","LU0708995401.HKD","IE00BK4W5M84.HKD","LU2471134952.CNY","LU0456855351.SGD","LU2237438978.USD","LU1232071149.USD","LU1989771016.USD","IE0002141913.USD","LU0198837287.USD","LU1093756325.SGD","BK4585","LU1720051017.SGD","LU2357305700.SGD","LU0354030511.USD","LU2750360997.AUD"],"gpt_icon":0},{"id":"1174034063","title":"异动解读 | 诺和诺德股价盘中暴跌8.08%，减肥药市场竞争加剧引发投资者担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1174034063","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174034063?lang=zh_cn&edition=full","pubTime":"2025-04-17 21:34","pubTimestamp":1744896881,"startTime":"0","endTime":"0","summary":"丹麦制药巨头诺和诺德今日盘中股价大跌8.08%，延续了该公司近期的下行趋势，反映出投资者对公司在竞争激烈的减肥药市场中面临的挑战日益担忧。值得注意的是，诺和诺德的股价自去年年中以来已经出现大幅回调。公司市值从去年的峰值6000亿美元大幅缩水，目前市盈率已降至20倍以下。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVO"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":-0.071},{"period":"1month","weight":-0.2205},{"period":"3month","weight":-0.2564},{"period":"6month","weight":-0.4741},{"period":"1year","weight":-0.5217},{"period":"ytd","weight":-0.3035}],"compareEarnings":[{"period":"1week","weight":-0.0193},{"period":"1month","weight":-0.0651},{"period":"3month","weight":-0.1306},{"period":"6month","weight":-0.0898},{"period":"1year","weight":0.0551},{"period":"ytd","weight":-0.1004}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novo Nordisk A/S成立于1989年，由两家丹麦公司Nordisk Gentofte A/S和Novo Industri A/S合并而成。该公司是一家全球医疗保健公司，也是糖尿病和肥胖症护理领域的全球领导者。该公司拥有广泛的糖尿病和肥胖症护理以及罕见疾病产品组合，包括用于治疗糖尿病和肥胖症的胰高血糖素样肽-1(GLP-1)受体激动剂、现代胰岛素和人胰岛素。","yearOnYearQuotes":[{"month":1,"riseRate":0.522727,"avgChangeRate":0.119015},{"month":2,"riseRate":0.613636,"avgChangeRate":0.028062},{"month":3,"riseRate":0.454545,"avgChangeRate":0.006986},{"month":4,"riseRate":0.613636,"avgChangeRate":0.01291},{"month":5,"riseRate":0.545455,"avgChangeRate":0.017073},{"month":6,"riseRate":0.704545,"avgChangeRate":0.027554},{"month":7,"riseRate":0.5,"avgChangeRate":0.005498},{"month":8,"riseRate":0.522727,"avgChangeRate":0.001751},{"month":9,"riseRate":0.568182,"avgChangeRate":-0.002657},{"month":10,"riseRate":0.5,"avgChangeRate":-0.002241},{"month":11,"riseRate":0.613636,"avgChangeRate":0.027229},{"month":12,"riseRate":0.727273,"avgChangeRate":0.04916}],"exchange":"NYSE","name":"诺和诺德","nameEN":"Novo-Nordisk A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺和诺德,NVO,诺和诺德股票,诺和诺德股票老虎,诺和诺德股票老虎国际,诺和诺德行情,诺和诺德股票行情,诺和诺德股价,诺和诺德股市,诺和诺德股票价格,诺和诺德股票交易,诺和诺德股票购买,诺和诺德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}